Table 1.
Main characteristics of 16 articles included in meta-analysis
| Study ID | Country | Ethnicity | Sample size | Mean age | MiR-16 | Cancer | Control | Specimen | Diagnostic power | QUADAS | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
||||||||||||||
| Case | Control | Case | Control | TP | FP | FN | TN | ||||||||
| Ichimi T, 2009 | Japan | Asian | 104 | 31 | 76 | 70 | miR-195 | Breast cancer | Healthy control | Serum | 95 | 6 | 9 | 25 | 3 |
| Heneghan HM, 2010 | Ireland | Caucasian | 83 | 63 | 55.1 | 52.1 | miR-195 | Breast cancer | Healthy control | Blood | 73 | 6 | 10 | 57 | 5 |
| Baraniskin A, 2011 | Germany | Caucasian | 23 | 30 | 64 | N.A. | miR-15b | PCNSL | Neurologic disorder | CSF | 21 | 7 | 2 | 23 | 4 |
| Mahn R, 2011 | Germany | Caucasian | 37 | 38 | N.A. | N.A. | miR-16 | Prostate cancer | HBV, Healthy control | Serum | 20 | 12 | 17 | 26 | |
| 37 | 38 | N.A. | N.A. | miR-195 | Prostate cancer | BPH | Serum | 28 | 16 | 9 | 22 | ||||
| Qu KZ, 2011 | USA | Caucasian | 105 | 107 | 55 | 51 | miR-16 | Liver cancer | Chronic liver disease | Serum | 76 | 12 | 29 | 95 | 5 |
| Bryant RJ, 2012 | UK | Caucasian | 78 | 28 | 70 | 63 | miR-107 | Prostate cancer | Healthy control | Plasma | 52 | 16 | 26 | 12 | 4 |
| Fang C, 2012 | China | Asian | 75 | 77 | 55.36 | 54 | miR-15a | DLBCL | Healthy control | Serum | 60 | 18 | 15 | 59 | 3 |
| 75 | 77 | 55.36 | 54 | miR-16 | DLBCL | Healthy control | Serum | 71 | 37 | 4 | 40 | ||||
| Maclellan SA, 2012 | Canada | Caucasian | 33 | 26 | 63 | 62 | miR-16 | Oral cancer | Healthy control | Serum | 20 | 2 | 13 | 24 | 4 |
| Miah S, 2012 | UK | Caucasian | 68 | 53 | 71 | 58 | miR-15a | Bladder cancer | Benign urinary disease | Urine | 35 | 15 | 33 | 38 | 5 |
| 68 | 53 | 71 | 58 | miR-15b | Bladder cancer | Benign urinary disease | Urine | 46 | 10 | 22 | 43 | ||||
| Wang X, 2012 | China | Asian | 50 | 50 | 49.86 | 48.55 | miR-103 | Breast cancer | Healthy control | Serum | 42 | 15 | 8 | 35 | 3 |
| Liu X, 2013 | China | Asian | 217 | 73 | 45.93 | 40.08 | miR-16 | Nasopharyngeal cancer | Nasopharyngitis | Plasma | 149 | 36 | 68 | 37 | 3 |
| Ng EK, 2013 | Hong Kong | Asian | 185 | 145 | 59 | 58 | miR-16 | Breast cancer | Healthy control | Plasma | 161 | 16 | 24 | 129 | 4 |
| Yang C, 2013 | China | Asian | 133 | 80 | N.A. | 46.8 | miR-15b | Astrocytoma | Healthy control | Serum | 113 | 16 | 20 | 64 | 4 |
| Tsukamoto O, 2014 | Japan | Asian | 28 | 14 | N.A. | N.A. | miR-195 | Endometrial cancer | Healthy control | Tissue | 25 | 2 | 3 | 12 | 5 |
| Zhu C, 2014 | China | Asian | 40 | 40 | 53.83 | 53.55 | miR-16 | Gastric cancer | Healthy control | Plasma | 36 | 2 | 4 | 38 | 3 |
N.A., not available; PCNSL, primary central nervous system lymphoma; DLBCL, diffuse large B cell lymphoma; BPH, benign prostate hyperplasia; UCC, urothelial cell carcinoma; CSF, cerebrospinal fluid; QUADAS, quality assessment of diagnostic accuracy studies.